![](/assets/icon.png)
1. The Response Evaluation Criteria in Solid Tumors (RECIST) were developed and published in 2000, based on the original World Health Organization (WHO) guidelines first published in 1981.
2. In 2009, revisions were made (RECIST 1.1) incorporating major changes, including a reduction in the number of lesions to be assessed, a clarification of the requirement to confirm a complete response (CR) or partial response (PR), and updated methodologies for more appropriate measurement of disease progression.
3. The purpose of this paper is to summarize the questions posed and the clarifications provided as an update to the 2009 publication.
The article titled "RECIST 1.1 – Update and Clarification: From the RECIST Committee" provides an overview of the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, which were developed to standardize response assessment using tumor shrinkage based on imaging modalities. The article highlights the changes made in the revised guidelines (RECIST 1.1) published in 2009, including a reduction in the number of lesions to be assessed, a new measurement method to classify lymph nodes as pathologic or normal, and new methodologies for more appropriate measurement of disease progression.
While the article provides useful information on the RECIST guidelines and their updates, it is important to note that it is written by members of the RECIST committee, which may introduce potential biases towards promoting their guidelines. Additionally, the article does not explore any counterarguments or criticisms of the RECIST criteria.
One limitation of this article is that it does not provide evidence for some of its claims, such as stating that RECIST has gained widespread adoption and is widely used in oncology clinical trials without providing any data or sources to support this claim. Furthermore, while the article acknowledges that there have been substantial changes in cancer therapeutics and imaging technology since RECIST was first developed, it does not address how these changes may impact the validity and applicability of RECIST criteria.
Another limitation is that while the article addresses frequently asked questions about RECIST 1.1, it does not provide comprehensive guidance on how to apply these guidelines in specific clinical scenarios or with different types of cancer therapies. This may limit its usefulness for clinicians who are looking for more detailed guidance on how to use RECIST criteria in practice.
Overall, while this article provides a useful summary of the RECIST guidelines and their updates, readers should be aware of potential biases towards promoting these guidelines and limitations in terms of evidence-based support and practical guidance for clinicians.